PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France

C Chouaid,L Bensimon,J Tardu,A Millier,R Insinga,A Rai,L Levy-Bachelot,P Levy

doi:10.1016/j.jval.2020.08.201

PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France

C Chouaid, L Bensimon + Show 6 more

Open Access

https://doi.org/10.1016/j.jval.2020.08.201

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2020
Citations: 1	License type: publisher-specific-oa

Affiliation: MSD (France), Creativ-Ceutical (France), United States Military Academy, Université Paris Sciences et Lettres, Université Paris Dauphine-PSL

#Metastatic Squamous NON-SMALL Cell LUNG #Squamous Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France

Full Text